Clinical trial
Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney…
NCT00227760 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00227760 |
|---|---|
| Title | Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery |
| Official title | A Phase 2 Study of AZD2171 in Progressive Unresectable, Recurrent or Metastatic Renal Cell Carcinoma (RCC) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer |
| Intervention type | Drug, Other, Procedure |
| Interventions | Cediranib Maleate, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Laboratory Biomarker Analysis, Pharmacological Study |
| Enrollment | 44 |
| Start date | Dec 1, 2005 |
| Primary completion | May 1, 2013 |
| Completion | May 1, 2013 |
| First posted | Sep 28, 2005 |
| Last update posted | Feb 29, 2016 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: